A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT ID: NCT06459180
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
686 participants
INTERVENTIONAL
2024-07-24
2028-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sacituzumab Tirumotecan
Participants will receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation.
Sacituzumab Tirumotecan
IV infusion
Treatment of Physician's Choice (TPC)
At the physician's discretion, participants will receive 500 mg/m\^2 of pemetrexed on day 1 of every 3-week cycle via IV infusion OR 2 mg/kg of tisotumab vedotin on day 1 of every 3-week cycle via IV infusion OR 1 mg/m\^2 (or 1.25 mg/m\^2 if tolerating well) topotecan on days 1, 2, 3, 4, and 5 of every 3-week cycle via IV infusion OR 30 mg/m\^2 of vinorelbine on days 1 and 8 of every 3-week cycle via IV infusion OR 1000 mg/m\^2 of gemcitabine on day 1 and 8 of every 3-week cycle via IV infusion OR 100 mg/m\^2 (or 125 mg/m\^2 if tolerating well) of irinotecan on days 1, 8, 15, and 22 of every 6 week cycle via IV infusion, until progressive disease or discontinuation.
Pemetrexed
IV infusion
Tisotumab Vedotin
IV infusion
Topotecan
IV infusion
Vinorelbine
IV infusion
Gemcitabine
IV infusion
Irinotecan
IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sacituzumab Tirumotecan
IV infusion
Pemetrexed
IV infusion
Tisotumab Vedotin
IV infusion
Topotecan
IV infusion
Vinorelbine
IV infusion
Gemcitabine
IV infusion
Irinotecan
IV infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have recurrent or metastatic cervical cancer that has progressed on or after treatment with 1 prior line of systemic platinum doublet chemotherapy (with or without bevacizumab) AND must have received anti-PD-1/anti-PD-L1 therapy as part of prior cervical cancer regimens
* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, as assessed by the investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions
* Is assigned female sex at birth, at least 18 years of age at the time of providing the informed consent
* Has ECOG performance status of 0 or 1 within 7 days before allocation for the Sacituzumab Tirumotecan Run-in or within 7 days before randomization for the Phase 3 portion
* Has provided tumor tissue (most recent sample is preferred) from a core or excisional biopsy of a tumor lesion not previously irradiated
* HIV-infected participants must have well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART)
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation (Sacituzumab Tirumotecan Run-in) or randomization (Phase 3 portion)
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
* Has adequate organ function
Exclusion Criteria
* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.
* Received prior systemic anticancer therapy
* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
* Has other histological subtypes of cervical cancer apart from squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (eg, carcinosarcoma), or has a diagnosis of nonepithelial cancer (eg, sarcoma, neuroendocrine tumors) of the cervix.
* Known additional malignancy that is progressing or has required active treatment within the past 3 years
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Active infection requiring systemic therapy
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Concurrent active Hepatitis B and active Hepatitis C virus infection
* Severe hypersensitivity (≥Grade 3) to sacituzumab tirumotecan or treatment of physician's choice (TPC) and/or any of their excipients, or other biologic therapy
* Participants who have not adequately recovered from major surgery or have ongoing surgical complications
* Has a history of (noninfectious) pneumonitis/ILD that required steroids or has current pneumonitis/ILD
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
GOG Foundation
NETWORK
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USA Mitchell Cancer Institute-Clinical Trials ( Site 4126)
Mobile, Alabama, United States
Providence Alaska Medical Center ( Site 4137)
Anchorage, Alaska, United States
HonorHealth (HH) ( Site 8002)
Phoenix, Arizona, United States
Arizona Oncology Associates - HOPE ( Site 8001)
Tucson, Arizona, United States
Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125)
La Jolla, California, United States
UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4105)
Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian ( Site 4104)
Newport Beach, California, United States
Mount Sinai Comprehensive Cancer Center ( Site 4143)
Miami Beach, Florida, United States
Advent Health ( Site 4140)
Orlando, Florida, United States
Florida Cancer Specialists East ( Site 7001)
West Palm Beach, Florida, United States
Northside Hospital ( Site 4127)
Atlanta, Georgia, United States
Georgia Cancer Center at Augusta University ( Site 4112)
Augusta, Georgia, United States
Lewis Cancer and Research Pavilion ( Site 4114)
Savannah, Georgia, United States
University Medical Center New Orleans ( Site 4132)
New Orleans, Louisiana, United States
Willis Knighton Medical Center ( Site 4101)
Shreveport, Louisiana, United States
The Center of Hope ( Site 4106)
Reno, Nevada, United States
Holy Name Medical Center ( Site 4117)
Teaneck, New Jersey, United States
Optimum Clinical Research Group ( Site 4138)
Albuquerque, New Mexico, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 4121)
New York, New York, United States
Duke Cancer Institute ( Site 4120)
Durham, North Carolina, United States
University of Cincinnati Medical Center ( Site 4128)
Cincinnati, Ohio, United States
The Ohio State University ( Site 4103)
Hilliard, Ohio, United States
Oklahoma Cancer Specialists and Research Institute, LLC-Clinical Research ( Site 4116)
Tulsa, Oklahoma, United States
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)
Eugene, Oregon, United States
Legacy Good Samaritan Medical Center-Oncology Clinical Research ( Site 4115)
Portland, Oregon, United States
Sidney Kimmel Cancer Center - Jefferson Health ( Site 4142)
Philadelphia, Pennsylvania, United States
Asplundh Cancer Pavilion ( Site 4113)
Willow Grove, Pennsylvania, United States
Texas Oncology - DFW ( Site 8003)
Fort Worth, Texas, United States
Houston Methodist Hospital OB/GYN ( Site 4102)
Houston, Texas, United States
Texas Oncology - San Antonio ( Site 8006)
San Antonio, Texas, United States
University of Virginia Cancer Center ( Site 4123)
Charlottesville, Virginia, United States
Inova Schar Cancer Institute ( Site 4139)
Fairfax, Virginia, United States
Swedish Medical Center-Swedish Cancer Institute ( Site 4134)
Seattle, Washington, United States
Hospital Británico de Buenos Aires-Oncology ( Site 0102)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0107)
Mar del Plata, Buenos Aires, Argentina
Instituto de Oncología Angel H. Roffo ( Site 0103)
Buenos Aires, Buenos Aires F.D., Argentina
Instituto Alexander Fleming ( Site 0108)
Buenos Aires, Buenos Aires F.D., Argentina
Sanatorio Allende - Cerro-Oncology ( Site 0106)
Córdoba, Córdoba Province, Argentina
Hospital Aleman-Oncology ( Site 0100)
Buenos Aires, , Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0109)
CABA, , Argentina
Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0104)
La Rioja, , Argentina
Blacktown Hospital ( Site 3006)
Sydney, New South Wales, Australia
Campbelltown Hospital-Macarthur Cancer Therapy Centre Medical Oncology ( Site 3000)
Sydney, New South Wales, Australia
Royal Brisbane and Women's Hospital ( Site 3001)
Herston, Queensland, Australia
Monash Health-Oncology Research ( Site 3002)
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 3005)
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital ( Site 3003)
Nedlands, Western Australia, Australia
Medizinische Universität Graz-Abteilung für Gynäkologie / Onkologie ( Site 1003)
Graz, Styria, Austria
Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 1000)
Innsbruck, Tyrol, Austria
Kepler Universitätsklinikum-Department for Oncology and Hematology ( Site 1002)
Linz, Upper Austria, Austria
Medizinische Universität Wien ( Site 1001)
Vienna, , Austria
AZORG Campus Aalst-Moorselbaan ( Site 2905)
Aalst, Oost-Vlaanderen, Belgium
UZ Gent-Medical oncology ( Site 2901)
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven-Gynecologic Oncology ( Site 2900)
Leuven, Vlaams-Brabant, Belgium
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman-Medical Oncology ( Site 2904)
Belgium, Wallonne, Region, Belgium
CHU UCL Namur/Site Sainte Elisabeth-Trial Office ( Site 2902)
Namur, , Belgium
Instituto do Câncer e Transplante de Curitiba ( Site 0205)
Curitiba, Paraná, Brazil
Hospital Moinhos de Vento-Centro de Pesquisa Clínica ( Site 0204)
Porto Alegre, Rio Grande do Sul, Brazil
Hospital do Câncer Mãe de Deus ( Site 0201)
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Hematologia e Oncologia ( Site 0203)
Joinville, Santa Catarina, Brazil
IBCC - Instituto Brasileiro de Controle do Câncer-Centro de Pesquisa Clínica ( Site 0200)
São Paulo, São Paulo, Brazil
Americas Centro de Oncologia Integrado ( Site 0202)
Rio de Janeiro, , Brazil
Hospital Paulistano ( Site 0209)
São Paulo, , Brazil
MBAL Uni Hospital-Department of Medical Oncology ( Site 1104)
Panagyurishte, Pazardzhik, Bulgaria
MHAT - Heart and Brain ( Site 1100)
Pleven, , Bulgaria
Complex Oncology Center - Plovdiv EOOD ( Site 1102)
Plovdiv, , Bulgaria
BC Cancer Kelowna ( Site 4007)
Kelowna, British Columbia, Canada
BC Cancer Surrey ( Site 4006)
Surrey, British Columbia, Canada
BC Cancer Victoria ( Site 4008)
Victoria, British Columbia, Canada
Royal Victoria Regional Health Centre ( Site 4009)
Barrie, Ontario, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 4003)
Hamilton, Ontario, Canada
Centre Hospitalier de l'Université de Montréal ( Site 4001)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 4000)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 4002)
Québec, Quebec, Canada
FALP-UIDO ( Site 0300)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 0302)
Santiago, Region M. de Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 0303)
Viña del Mar, Región de Valparaíso, Chile
Anhui Provincial Cancer Hospital-Gynecological Oncology ( Site 5040)
Hefei, Anhui, China
Anhui Provincial Hospital ( Site 5011)
Hefei, Anhui, China
Beijing Peking Union Medical College Hospital ( Site 5045)
Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital ( Site 5003)
Chongqing, Chongqing Municipality, China
Fujian Provincial Cancer Hospial ( Site 5012)
Fuzhou, Fujian, China
The First Affiliated hospital of Xiamen University-Obstetrics and gynecology department ( Site 5027)
Xiamen, Fujian, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 5001)
Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center-Internal medicine ( Site 5006)
Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University ( Site 5004)
Zhanjiang, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 5016)
Nanning, Guangxi, China
Hainan General Hospital ( Site 5032)
Haikou, Hainan, China
Harbin Medical University Cancer Hospital ( Site 5010)
Harbin, Heilongjiang, China
The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 5041)
Xinxiang, Henan, China
Henan Cancer Hospital ( Site 5026)
Zhengzhou, Henan, China
Wuhan Union Hospital ( Site 5020)
Wuhan, Hubei, China
Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 5019)
Wuhan, Hubei, China
Hunan Cancer Hospital ( Site 5021)
Changsha, Hunan, China
Xiangya Hospital Central South University ( Site 5009)
Changsha, Hunan, China
Jiangsu Province Hospital-Oncology Department ( Site 5018)
Nanjing, Jiangsu, China
Jiangxi Maternal and Child Health Hospital ( Site 5031)
Nanchang, Jiangxi, China
Jilin Province Tumor Hospital ( Site 5036)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 5007)
Xi'an, Shaanxi, China
Shandong Cancer Hospital ( Site 5014)
Jinan, Shandong, China
LinYi Cancer Hospital-Gastrology department ( Site 5039)
Linyi, Shandong, China
Obstetrics & Gynecology Hospital of Fudan University ( Site 5015)
Shanghai, Shanghai Municipality, China
Shanxi Cancer Hospital ( Site 5043)
Taiyuan, Shanxi, China
West China Second University Hospital, Sichuan University ( Site 5017)
Chengdu, Sichuan, China
Sichuan Cancer hospital-Oncology ( Site 5030)
Chengdu, Sichuan, China
Yunnan Province Cancer Hospital-Gynecology Department ( Site 5005)
Kunming, Yunnan, China
Women s Hospital School of Medicine Zhejiang University ( Site 5022)
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital ( Site 5008)
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University ( Site 5033)
Wenzhou, Zhejiang, China
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0403)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0401)
Valledupar, Cesar Department, Colombia
Instituto Nacional De Cancerologia-Oncología Clínica ( Site 0404)
Bogota, Cundinamarca, Colombia
IMAT S.A.S ( Site 0402)
Montería, Departamento de Córdoba, Colombia
Oncologos del Occidente ( Site 0405)
Pereira, Risaralda Department, Colombia
Fundación Valle del Lili ( Site 0406)
Cali, Valle del Cauca Department, Colombia
Rigshospitalet-Dept. of Oncology ( Site 1300)
Copenhagen, Capital Region, Denmark
Aarhus Universitetshospital, Skejby ( Site 1301)
Aarhus, Central Jutland, Denmark
Odense Universitetshospital-Department of oncology ( Site 1302)
Odense C, Region Syddanmark, Denmark
Tampereen yliopistollinen sairaala-Gynecology and Obstetrics ( Site 1404)
Tampere, Pirkanmaa, Finland
Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1401)
Turku, Southwest Finland, Finland
Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1400)
Helsinki, Uusimaa, Finland
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1501)
Strasbourg, Alsace, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 1503)
Bordeaux, Aquitaine, France
CENTRE LEON BERARD ( Site 1505)
Lyon Cedex08, Auvergne-Rhône-Alpes, France
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 1508)
Clermont-Ferrand, Auvergne, France
Institut Paoli-Calmettes ( Site 1504)
Marseille, Bouches-du-Rhone, France
Hôpital Privé Des Côtes d'Armor ( Site 1510)
Plérin, Cotes-d Armor, France
CHU Besançon ( Site 1507)
Besançon, Franche-Comte, France
Oncopole Claudius Regaud ( Site 1502)
Toulouse, Haute-Garonne, France
Institut Regional du Cancer Montpellier ( Site 1511)
Montpellier, Herault, France
Hôpital privé du Confluent SAS ( Site 1509)
Nantes, Loire-Atlantique, France
Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 1506)
Paris, , France
Gustave Roussy ( Site 1512)
Villejuif, Île-de-France Region, France
SLK-Kliniken Heilbronn ( Site 1617)
Heilbronn, Baden-Wurttemberg, Germany
Diakonie-Klinikum Schwaebisch-Hall gGmbH Frauenklinik ( Site 1614)
Schwäbisch Hall, Baden-Wurttemberg, Germany
Universitätsklinikum Marburg ( Site 1604)
Marburg, Hesse, Germany
Universitaetsklinikum Duesseldorf-Klinik für Frauenheilkunde & Geburtshilfe ( Site 1607)
Düsseldorf, North Rhine-Westphalia, Germany
Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung-Klinik für Gynäkologie und Gynäkologische Onko ( Site 1600)
Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen ( Site 1613)
Essen, North Rhine-Westphalia, Germany
Klinikum Worms ( Site 1619)
Worms, Rhineland-Palatinate, Germany
Universitaetsklinikum des Saarlandes ( Site 1618)
Homburg, Saarland, Germany
Aretaieio Hospital ( Site 1700)
Athens, Attica, Greece
Mitera Hospital ( Site 1702)
Athens, Attica, Greece
ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1703)
Chaïdári, Attica, Greece
Agios Andreas Hospital Patras ( Site 1701)
Patras, Peloponnese, Greece
Cork University Hospital ( Site 1900)
Cork, , Ireland
Mater Misericordiae University Hospital ( Site 1901)
Dublin, , Ireland
St. James's Hospital-Cancer clinical trials office ( Site 1902)
Dublin, , Ireland
Rambam Health Care Campus ( Site 2002)
Haifa, , Israel
Edith Wolfson Medical Center ( Site 2003)
Holon, , Israel
Hadassah Medical Center ( Site 2000)
Jerusalem, , Israel
Sheba Medical Center ( Site 2001)
Ramat Gan, , Israel
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlin-DEPARTMENT OF EXPERIMENTAL, DIAGNOSTIC ( Site 2105)
Bologna, Emilia-Romagna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 2107)
Milan, Lombardy, Italy
Istituto Europeo di Oncologia IRCCS ( Site 2108)
Milan, Lombardy, Italy
Ospedale Humanitas San Pio X ( Site 2113)
Milan, Lombardy, Italy
Fondazione IRCCS San Gerardo dei Tintori-Oncologia ( Site 2111)
Monza, Lombardy, Italy
Humanitas University ( Site 2112)
Rozzano, Milano, Italy
Ospedale Mauriziano-SCDU ONCOLOGIA MEDICA ( Site 2100)
Turin, Piedmont, Italy
Azienda Ospedaliera Spedali Civili di Brescia-Obstetrics anf gynecology ( Site 2110)
Brescia, , Italy
Ospedale Cannizzaro ( Site 2104)
Catania, , Italy
Ospedale San Raffaele. ( Site 2106)
Milan, , Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 2103)
Napoli, , Italy
Istituto Oncologico Veneto IRCCS ( Site 2109)
Padua, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2102)
Roma, , Italy
Aichi Cancer Center ( Site 5110)
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 5113)
Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 5109)
Matsuyama, Ehime, Japan
Ehime University Hospital ( Site 5102)
Tōon, Ehime, Japan
Kurume University Hospital ( Site 5105)
Kurume, Fukuoka, Japan
Gunma Prefectural Cancer Center ( Site 5116)
Ohta, Gunma, Japan
Hokkaido University Hospital ( Site 5106)
Sapporo, Hokkaido, Japan
University of Tsukuba Hospital ( Site 5114)
Tsukuba, Ibaraki, Japan
Iwate Medical University Hospital ( Site 5112)
Shiwa-gun, Iwate, Japan
Saitama Medical University International Medical Center ( Site 5117)
Hidaka, Saitama, Japan
Shizuoka Cancer Center ( Site 5107)
Sunto-gun,, Shizuoka, Japan
National Cancer Center Hospital ( Site 5108)
Chūō, Tokyo, Japan
Cancer Institute Hospital of JFCR ( Site 5111)
Koto, Tokyo, Japan
The Jikei University Hospital ( Site 5118)
Minato, Tokyo, Japan
Keio University Hospital ( Site 5101)
Shinjyuku, Tokyo, Japan
National Hospital Organization Kyushu Cancer Center ( Site 5104)
Fukuoka, , Japan
Kagoshima City Hospital ( Site 5115)
Kagoshima, , Japan
Niigata Cancer Center Hospital ( Site 5100)
Niigata, , Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5103)
Osaka, , Japan
University Malaya Medical Centre ( Site 3102)
Lembah Pantai, Kuala Lumpur, Malaysia
Sunway Medical Centre ( Site 3105)
Petaling Jaya, Selangor, Malaysia
Pantai Hospital Kuala Lumpur ( Site 3100)
Kuala Lumpur, , Malaysia
Penang Adventist Hospital ( Site 3101)
Pulau Pinang, , Malaysia
CENEIT Oncologicos ( Site 0507)
Mexico City, Mexico City, Mexico
Oncare - Unidad Valle ( Site 0509)
San Pedro Garza García, Nuevo León, Mexico
Centro de Investigacion Clinica de Oaxaca ( Site 0505)
Oaxaca City, Oaxaca, Mexico
Centro de Investigación Oncológica Galerías SC ( Site 0508)
Aguascalientes, , Mexico
Centro de Atención e Investigación Cardiovascular del Potosí ( Site 0506)
San Luis Potosí City, , Mexico
Radboudumc-Medical Oncology ( Site 2202)
Nijmegen, Gelderland, Netherlands
Catharina Ziekenhuis-Oncology ( Site 2203)
Eindhoven, North Brabant, Netherlands
Amsterdam UMC, locatie VUmc ( Site 2201)
Amsterdam, North Holland, Netherlands
Erasmus Medisch Centrum-Medical Oncology ( Site 2200)
Rotterdam, South Holland, Netherlands
University Medical Center Groningen ( Site 2204)
Groningen, , Netherlands
Oslo universitetssykehus, Radiumhospitalet ( Site 2300)
Oslo, , Norway
Uniwersytecki Szpital Kliniczny w Poznaniu-Oddzial Ginekologii Onkologicznej ( Site 2404)
Poznan, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Site 2400)
Warsaw, Masovian Voivodeship, Poland
Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 2402)
Bialystok, Podlaskie Voivodeship, Poland
UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 0601)
San Juan, , Puerto Rico
National University Hospital ( Site 3301)
Singapore, Central Singapore, Singapore
National Cancer Centre Singapore ( Site 3300)
Singapore, Central Singapore, Singapore
Seoul National University Hospital ( Site 3403)
Seoul, , South Korea
Severance Hospital, Yonsei University Health System ( Site 3402)
Seoul, , South Korea
Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 3401)
Seoul, , South Korea
Samsung Medical Center ( Site 3400)
Seoul, , South Korea
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2509)
Barcelona, Catalonia, Spain
Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2508)
L'Hospitalet de Llobregat, Catalonia, Spain
Institut Català d'Oncologia (ICO) - Girona-Oncología Médica ( Site 2507)
Girona, Gerona, Spain
Clinica Universidad de Navarra ( Site 2510)
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 2502)
Madrid, Madrid, Comunidad de, Spain
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 2506)
Madrid, Madrid, Comunidad de, Spain
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 2503)
Valencia, Valenciana, Comunitat, Spain
HOSPITAL CLINICO DE VALENCIA ( Site 2505)
Valencia, Valenciana, Comunitat, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2500)
Barcelona, , Spain
Hospital Universitario Reina Sofia-Oncologia Medica ( Site 2501)
Córdoba, , Spain
Hospital Universitario La Paz-Oncología Médica ( Site 2504)
Madrid, , Spain
Skånes Universitetssjukhus Lund-Department of Hematology ( Site 2602)
Lund, Skåne County, Sweden
Karolinska Universitetssjukhuset Solna ( Site 2601)
Stockholm, Stockholm County, Sweden
Akademiska sjukhuset ( Site 2603)
Uppsala, Uppsala County, Sweden
Universitetssjukhuset i Linköping ( Site 2600)
Linköping, Östergötland County, Sweden
University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 2701)
Basel, Canton of Basel-City, Switzerland
Inselspital Bern-Oncology ( Site 2700)
Bern, , Switzerland
ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre ( Site 2807)
London, England, United Kingdom
Royal Marsden Hospital (Sutton)-Gynaecology Unit ( Site 2801)
Sutton, England, United Kingdom
Gartnavel General Hospital-Clinical Trials Unit ( Site 2800)
Glasgow, Glasgow City, United Kingdom
University College London Hospital ( Site 2805)
London, London, City of, United Kingdom
St James's University Hospital ( Site 2804)
Leeds, , United Kingdom
The Christie NHS Foundation Trust-Research and Development ( Site 2802)
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Study Coordinator
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Plain Language Summary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-2870-020
Identifier Type: OTHER
Identifier Source: secondary_id
TroFuse-020
Identifier Type: OTHER
Identifier Source: secondary_id
2023-508323-12-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
U1111-1298-0563
Identifier Type: REGISTRY
Identifier Source: secondary_id
GOG-3101
Identifier Type: OTHER
Identifier Source: secondary_id
ENGOT-cx20
Identifier Type: OTHER
Identifier Source: secondary_id
jRCT2031240201
Identifier Type: REGISTRY
Identifier Source: secondary_id
2870-020
Identifier Type: -
Identifier Source: org_study_id